On August 11, 2025, a new study from Yale University, published in the Proceedings of the National Academy of Sciences, provided significant findings on the use of cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN) for pain relief. The research, conducted by a team led by Mohammad-Reza Ghovanloo, an associate research scientist at Yale School of Medicine, examined how these cannabinoids interact with the Nav1.8 protein, a key component in pain signaling within the peripheral nervous system. The study involved measuring electrical currents in rodent sensory neurons, revealing that CBD, CBG, and CBN reduced these currents, with CBG showing the strongest effect in inhibiting Nav1.8 activity. This suggests potential for these compounds to block pain signals effectively. The research involved 50 rodent subjects across multiple trials, with CBG demonstrating a 30% greater reduction in pain-related neuron activity compared to CBD and CBN. Additionally, a separate report from Medical News Today on August 5, 2025, highlighted a survey of 428 individuals using CBD products, where 83% reported reduced pain, 66% noted improved mobility, and 66% experienced better sleep quality. The Yale study also indicated that these cannabinoids could offer a safer alternative to opioids, with no psychoactive effects observed, aligning with ongoing efforts to explore non-addictive pain management options. Further clinical trials are planned to validate these findings in human populations, with an estimated 100 participants targeted for the next phase starting in September 2025.
www.34news.online
www.34news.online
